8-KEarnings & ResultsExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (Feb 12, 2015)

Filed February 12, 2015For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. filed an 8-K on February 12, 2015, to announce its financial results for the fourth quarter and full year ended December 31, 2014. This report primarily serves to furnish the press release detailing these results, which provides investors with a snapshot of the company's financial performance and operational standing as of that date. The filing itself does not contain new operational or strategic details beyond what is presented in the accompanying press release, which is the key document for investors to review for comprehensive financial information and management's commentary. The significance of this filing lies in its role as the official dissemination of Alnylam's financial health for the period. Investors would look to the furnished press release (Exhibit 99.1) for details on revenue, net loss, cash position, and any updates on their drug development pipeline and clinical trial progress, which are critical indicators for a biotechnology company. This 8-K acts as the SEC-compliant record of these important financial disclosures.

Key Highlights

  • 1Alnylam Pharmaceuticals announced its financial results for the quarter and year ended December 31, 2014.
  • 2The report is an 8-K filing, indicating a significant event or change for the company.
  • 3The primary purpose of the filing is to furnish a press release containing the financial results (Exhibit 99.1).
  • 4Investors are directed to the press release for detailed financial performance information.
  • 5The filing confirms the date of the announcement as February 12, 2015.
  • 6Information furnished in this report is not considered 'filed' for certain SEC liability purposes, emphasizing reliance on the press release itself.
  • 7Michael P. Mason, Vice President, Finance and Treasurer, signed the report on behalf of Alnylam.

Frequently Asked Questions

The main purpose of this 8-K filing is to officially announce and furnish Alnylam Pharmaceuticals' financial results for the fourth quarter and full year ended December 31, 2014, through an accompanying press release.

The detailed financial results are provided in the press release dated February 12, 2015, which is furnished as Exhibit 99.1 to this 8-K filing.

This 8-K filing primarily serves to report financial results. For specific strategic updates or operational guidance beyond the financial performance, investors should refer to the content of the furnished press release.

The disclaimer indicates that the information provided in this 8-K (including the press release) is being reported to the SEC but is not subject to the same liabilities under Section 18 of the Exchange Act as information that is formally 'filed.' This means investors should rely on the press release for the definitive information, and it won't be automatically incorporated into other SEC filings unless explicitly referenced.